VYVGART is the first treatment that uses a fragment of an IgG antibody to treat adults with anti-AChR antibody positive gMG. VYVGART is a fragment of an IgG antibody.
VYVGART is specifically designed to attach to and block the neonatal Fc receptor (FcRn), resulting in the reduction of IgG antibodies, including the harmful AChR antibodies that cause gMG symptoms.
Receptors called “FcRn” extend the life of IgG antibodies.
In gMG, this allows harmful AChR antibodies to continue causing gMG symptoms. But IgG antibodies, including harmful AChR antibodies, that cannot attach to an FcRn are removed by the body.
When harmful AChR antibodies that cause gMG symptoms are removed, they can no longer disrupt nerve-muscle communication.
It's like trying to get a table at a busy restaurant, where FcRns are the tables. IgG antibodies that get a table can stay for dinner, but if there are no tables available, IgG antibodies have to leave. The same goes for VYVGART, but since VYVGART can take some tables, there are fewer tables available for IgG antibodies, including harmful AChR antibodies. Those who don’t get a table are then removed.
